New cancer drugs are less effective in real world settings than the results from the randomised controlled trials used to support their approval, US research shows. A review of outcomes for nine cancer drugs approved since 2008 for 14 indications found that overall survival (OS) rates in 2196 Medicare-eligible patients over the age of 65 ...
Oncology drug real world outcomes don’t match RCT results
By Michael Woodhead
20 Jun 2019